SI-BONE Stock Jumps 18% After Third-Quarter Revenue Growth and Reaffirmed Guidance

SI-BONE (Nasdaq: SIBN) shares rose 17.6% on Tuesday, Nov. 3, 2026, closing at $23.77 against a previous close of $20.22, while the S&P 500 ETF (SPY) gained 0.30%. Volume ran at 6.1 times its normal level. The move came in the first session after the company released third-quarter results on Monday, Nov. 2, in a press release filed with an 8-K.

Revenue growth and a narrower loss

Worldwide revenue rose 14.5% to $55.7 million in the third quarter from $48.7 million a year earlier. U.S. revenue grew 13.9% to $52.8 million, with U.S. procedure volume up about 19.5%. The net loss narrowed 20.7% to $3.6 million, or $0.08 a share, from $4.6 million, or $0.11 a share, a year earlier. Adjusted EBITDA was $3.0 million, compared with $2.3 million.

Guidance held, cost outlook trimmed

SI-BONE reaffirmed its 2026 revenue forecast of $231 million to $233 million and its gross margin outlook of about 79.0%. It lowered its operating expense growth expectation to 10.5% from 12.0%, based on year-to-date spending. Chief Executive Laura Francis said the company entered the fourth quarter with a record number of active physicians and "exceptional early uptake" of iFuse Granite Onyx, which received 510(k) clearance in September.

Cash and investments steady

The company reported $146.3 million in cash and short-term investments combined at Sept. 30, 2026, compared with $145.9 million at June 30. Net cash generated in the quarter was $0.4 million.